Preoperative Induction Therapy With 12 Weeks of Panitumumab in Combination With mFOLFOX-6 in an Enriched Population (Quadruple Wild-Type) of Patients With mrT3 Rectal Cancer of the Middle Third With Clear Mesorectal Fascia
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms PIER
- 01 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2020.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.
- 17 Feb 2017 Planned End Date changed from 1 Jul 2020 to 1 Oct 2020.